{"disease":{"id":"er-her2-metastatic-breast-cancer","name":"er her2 metastatic breast cancer"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"atezolizumab","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"talazoparib-tosylate","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"talazoparib-tosylate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP1, PARP2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":75,"revenue":"182","mechanism":"Talazoparib inhibits PARP enzymes, causing DNA damage and cell death in cancer cells with DNA repair defects."},{"drug_id":"talazoparib","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"talazoparib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 4","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":72,"revenue":"182","mechanism":"Talzenna blocks PARP enzymes, which are involved in DNA repair, to prevent cancer cell growth."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"alpelisib","indication_name":"Germline BRCA-mutated, HER2-negative metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piqray","generic_name":"alpelisib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"PI3Kα","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Alpelisib inhibits PI3Kα, blocking Akt-signaling and preventing tumor growth and organ abnormalities in PROS disorders."},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"imlunestrant","indication_name":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inluriyo","generic_name":"IMLUNESTRANT","company_name":"Eli Lilly And Co","drug_phase":"marketed","molecular_target":"","drug_class":"Estrogen Receptor Antagonist [EPC]","quality_score":61,"revenue":null,"mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05306340","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":373,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT06533826","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":357,"lead_sponsor_name":"Ana C Garrido-Castro, MD","has_results":false},{"nct_id":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03910712","title":"Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT01881230","title":"Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT06942234","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06062498","title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06756932","title":"BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT03584009","title":"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06774027","title":"Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02605915","title":"Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05927779","title":"Study of TFX06 in Women With Advanced Breast Cancer.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":74,"lead_sponsor_name":"Zhejiang Yangli Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07503717","title":"SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance","phase":"NA","overall_status":"RECRUITING","enrollment_count":69,"lead_sponsor_name":"Royal College of Surgeons, Ireland","has_results":false},{"nct_id":"NCT04090567","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04692831","title":"Testing a New Imaging Agent to Identify Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06570031","title":"ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04550494","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03691493","title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT06525766","title":"Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03291938","title":"IACS-010759 in Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03725436","title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04818632","title":"AZD9833 China PK Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05098210","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05826964","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT05036252","title":"Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05319873","title":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05555251","title":"BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT03207529","title":"Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04319757","title":"ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Acepodia Biotech, Inc.","has_results":false},{"nct_id":"NCT05054374","title":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT01217411","title":"RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04296942","title":"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT04498520","title":"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pamela Munster","has_results":false},{"nct_id":"NCT04351230","title":"T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}